Friday November 9, 2018 0 comments
LOUISVILLE -- Eximis Surgical, Inc. announced it secured $7.5 million in new financing led by Questa Capital with participation from Venture Investors.
Eximis Surgical is developing a transformational surgical platform for the removal of large specimens through small laparoscopic incisions.
The Eximis Laparoscopic Specimen Removal System is designed to keep incisions small throughout the minimally invasive procedure, providing fast, fully contained specimen segmentation and removal.
The technology fills a critical gap in minimally invasive surgery.
Eximis Surgical said it will use the new capital to fund U.S. regulatory approval and the commercial launch of the Eximis Laparoscopic Specimen Removal System.
As part of the financing, Ryan Drant, Questa Capital founder and managing director, and Scott Button, Venture Investors managing director, will join Eximis Surgical's board of directors.
"I am extremely pleased with the investment by Questa Capital and Venture Investors, and I look forward to partnering as we approach regulatory submission and approval," said Kristin Johnson, Eximis Surgical co-founder and CEO.
"Support from highly respected investors further validates our novel technology and enhances the capabilities of our experienced team."
"We at Questa are very pleased to invest in Eximis," said Drant. "Quick and safe large specimen removal is a major unmet need in minimally invasive surgery, and Eximis has developed a very compelling technology solution."
Eximis Surgical also announced that Ted Lamson and Scott Hutton recently joined the board as independent directors.
Lamson, NeoTract CTO, was the company's co-founder and founding president & CEO. NeoTract was acquired by Teleflex for up to $1.1 billion in 2017. Prior to founding NeoTract, Lamson was VP of R&D at TransVascular, a cardiovascular device company acquired by Medtronic in 2004. He holds a PhD in Bioengineering from Penn State University and a Bachelor of Science degree from Rensselaer Polytechnic Institute.
Hutton, Biodesix COO, previously served as senior VP and GM of Spectranetics' Vascular Intervention business, which was acquired by Philips in 2017. Prior to Spectranetics, Hutton spent 16 years with Medtronic, where he held several executive roles including VP and GM of the Neurosurgery business unit. He holds a Bachelor of Arts degree in Health and Kinesiology from Purdue University.
"We are excited to have Ted and Scott as members of Eximis' board of directors,” said Johnson. “Both are highly experienced medical device executives with proven successes in the surgical device space.
"Ted is a proven entrepreneur who has developed and marketed a disruptive technology that enables minimally invasive treatment for millions of BPH patients annually.
“Scott has successfully led and grown multi-million-dollar medical device businesses with cutting-edge technologies and brings a unique blend of commercial and business development experience."